Fagron NV (LON: 0HNZ)

Market Cap	1.12B
Revenue (ttm)	695.86M
Net Income (ttm)	66.08M
Shares Out	n/a
EPS (ttm)	0.91
PE Ratio	16.91
Forward PE	n/a
Dividend	0.18 (0.99%)
Ex-Dividend Date	May 21, 2024

Volume	313
Average Volume	2,955
Open	18.19
Previous Close	18.02
Day's Range	18.09 - 18.20
52-Week Range	13.10 - 16.47
Beta	0.26
RSI	60.58
Earnings Date	Feb 20, 2025

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan use...

• Industry: Medical, Dental, and Hospital Equipment and Supplies
• Founded: 1990
• Employees: 3,282
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HNZ

Financial Performance

In 2023, Fagron NV's revenue was 762.99 million, an increase of 11.57% compared to the previous year's 683.88 million. Earnings were 70.55 million, an increase of 1.34%.

Financial numbers in EUR